
Advertise on podcast: PharmOncology
Rating
5from
This podcast has
28 episodes
Language
EnglishPublisher
Ming-Hei TaiExplicit
No
Date created
2026/05/14
Latest episode
2026/11/11
Average duration
12 min.
Release period
8 days
Description
A podcast about pharmacy and oncology
Unlock PharmOncology podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from PharmOncology podcast
Why new first line DLBCL trials have two extra cycles of rituximab for R-CHOP
2026/11/11
Or alternatively, why the US and Europe disagree!
GELA/LNH 98-5: https://www.nejm.org/doi/full/10.1056/NEJMoa011795
SWOG E4494: https://pubmed.ncbi.nlm.nih.gov/16754935/
MinT: https://pubmed.ncbi.nlm.nih.gov/16648042/)
R-CHOP 14 vs 21: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60313-X/fulltext
RICOVER-60: https://pubmed.ncbi.nlm.nih.gov/18226581/
GOYA: https://ashpublications.org/blood/article/132/Supplement%201/783/266048/No-Added-Benefit-of-Eight-Versus-Six-Cycles-of
PETAL: https://ascopubs.org/doi/10.1200/JCO.2017.76.8093
FLYER: https://www.thelancet.com/article/S0140-6736(19)33008-9/fulltext
Savolitinib, osimertinib, and how we should be targeting EGFR mutated lung cancer after relapse
2026/11/04
SAFFRON trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
A Review of DeLLphi-305
2026/10/28
A quick review of tarlatamab's successful first line maintenance therapy trial
NEJM publication:
https://www.nejm.org/doi/10.1056/NEJMoa2609482
Is daraxonrasib actually pan-RAS?
2026/10/21
Daraxonrasib may be less effective in certain RAS mutations.
FDA review: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220910Orig1s000TOC.html
Preclinical daraxonrasib studies:
https://pubs.acs.org/jmcmar/article-abstract/68/6/6064/3643788/Discovery-of-Daraxonrasib-RMC-6236-a-Potent-and
https://pmc.ncbi.nlm.nih.gov/articles/PMC11149917/
Analysis of common KRAS mutations including GTPase activity:
https://aacrjournals.org/mcr/article/13/9/1325/89607/Biochemical-and-Structural-Analysis-of-Common
Resistance mechanisms to daraxonrasib:
https://aacrjournals.org/cancerres/article/85/8_Supplement_2/LB281/761862/Abstract-LB281-Mechanisms-of-resistance-to-the-RAS
How hepatotoxic is tucatinib?
2026/10/14
Why tucatinib had a black box warning for hepatotoxicity added
New FDA indication approval:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer
How do ADCs actually work?
2026/10/07
ADCs may not increase the therapeutic window
Cancer Cell commentary: https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00445-7
Clinical Trial Representativeness in Oncology
2026/09/30
Using myeloma as an example, why trial representativeness has a meaningful clinical impact in oncology
DETERMINATION trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2204925
Blood letter: https://ashpublications.org/blood/article/137/21/2987/475530/Incidence-of-skin-hyperpigmentation-in-Black
Why MMAE beat MMAF
2026/09/23
A story of two antibody drug conjugate payloads
Sequencing agents in HER2 mutant lung cancer
2026/09/16
How I think agents should be sequenced in HER2 mutant lung cancer.
Case report on zongertinib upregulating HER2 receptors: https://pmc.ncbi.nlm.nih.gov/articles/PMC12964209/
Does levetiracetam makes sense for ICANS?
2026/09/09
Why did we start using an anti-seizure medication for ICANS?
Study on levetiracetam: https://ashpublications.org/bloodadvances/article/9/21/5501/546533/Routine-prophylaxis-with-levetiracetam-offers-no
Is zanidatamab better than trastuzumab in HER2 IHC 2+?
2026/09/02
Thoughts on the HER2 3+ and HER2 2+/ISH+ subgroups for zanidatamab, and its mechanism of action
JACOB trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/abstract
INNOVATION trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.LBA331
HERIZON-GEA-01: https://www.nejm.org/doi/full/10.1056/NEJMoa2517729
Zanidatamab preclinical study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10011572/N
ESR1 mutations, elacestrant, imlunestrant, and vepdegestrant
2026/08/26
How ESR1 mutations develop in breast cancer, targeting them, and some differences between elacestrant, imlunestrant, and vepdegestrant
Explaining CELMoDs in 10 minutes
2026/08/19
Explaining CELMoDs. It's hard to pronounce ubiquitination!
JCO article on VTE events in clinical trials: https://ascopubs.org/doi/10.1200/JCO-25-00489
Does chemo work in extensive stage small cell lung cancer?
2026/08/12
With lurbinectedin being withdrawn from second line extensive stage small cell lung cancer, thoughts on what treatments have been effective in this aggressive cancer.
Why current HER2 testing is flawed
2026/08/05
Problems with how we currently test for HER2 and possible future directions.
Trastuzumab in endometrial cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC8792803/Issues with HER2 testing in endometrial cancer:
https://www.gynecologiconcology-online.net/article/S0090-8258(25)01072-8/fulltext
https://www.mdpi.com/2072-6694/18/12/2009Novel methods of testing for HER2: https://www.nature.com/articles/s41698-026-01365-6
Podcast sponsorship advertising
Start advertising on PharmOncology relevant audience podcasts
You may also like to advertise on these Podcasts

4.8219787
Imperfect Action
Steph Taylor

4.727637592
This Past Weekend w/ Theo Von
Theo Von

4.713055379
The Tim Dillon Show
The Tim Dillon Show

4.116097472
The Tucker Carlson Show
Tucker Carlson Network

4.828116459
Huberman Lab
Scicomm Media

4.240683
To Be The Man
Podcast Heat | Cumulus Podcast Network

4.41511762000
The Ben Shapiro Show
The Daily Wire

4.2155648
TENNIS.com Podcast
TENNIS.com Podcast/Tennis Channel Podcast Network

4.510882780
The Joe Budden Podcast
The Joe Budden Network

4.611699506
The Bulwark Podcast
The Bulwark